2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Gold loans grow 4x in 3 years, ticket size doubles t...
Mining equipment maker Eimco Elecon's Q4 profit cras...
Demand for crude oil to see biggest quarterly slump ...
Global pharma giants escape US regulation while test...
EV charging fees to be discounted on weekends: South...
India's AI infrastructure buildup will bolster South...
India's passenger vehicle sales jump 16 pc in March
From 'pharmacy of world' to innovation hub: PM Naren...
Government notifies new rules on fees for overloaded...
India can absorb energy shock but fiscal strains pos...
